Reasons to Invest in Evren’s Groundbreaking Drug-Free Solution to PTSD

Updated: Mar 29


In the past, mental health has not been taken seriously. As a result, there are limited resources for sufferers of mental illness.


Evren Technologies is here to change that. We believe mental health matters.


Evren is developing a portable, non-invasive device for the millions of Americans with PTSD. Current treatments are not getting the job done, leaving 66% of patients still seeking relief. Evren’s device, the Phoenix®, will provide personalized levels of vagal nerve stimulation to reduce PTSD symptom severity and improve quality of life without the harmful side effects seen with prescription drugs.


Whether it's a soldier returning from war, a survivor of traumatic violence or abuse, an individual who has experienced a serious car accident, or anyone else exposed to traumatic experiences and suffering from the effects of PTSD, Evren's technology can be used by anyone, anytime, and anywhere to manage their disorder.


As you may have heard, Evren Technologies is currently raising capital via StartEngine’s equity crowdfunding platform. Here are a few compelling reasons to join our community of early shareholders.

Why invest in Evren?

  • Evren's device, the Phoenix®, was recently awarded Breakthrough Device Designation by the FDA, demonstrating that it could provide better treatment than the current standard of care in the serious, life-threatening condition of Post-Traumatic Stress Disorder.


  • Evren is the recipient of the SBIR Phase I award for the development of a "Programmable tVNS research device for PTSD and related conditions."


  • Revolutionary technology for a massive, untapped market: Post-Traumatic Stress Disorder is a $22.5 billion-dollar market with 66% of those suffering seeking new treatment options.


  • 15 million Americans experience post-traumatic stress disorder in a given year, and over 60 million Americans suffered from PTSD during the height of the COVID shutdown.


  • All 100% of Phoenix® users wanted to continue using the device after the pilot trial, and all of them were willing to pay out-of-pocket for it.

Join Evren Technologies as an Early Shareholder

What are you waiting for? Head over to our StartEngine raise page and take advantage of our latest offering for as little as $399. We thank you in advance for your support!


18 views0 comments